• 

  Phil’s Journal: What’s Next for the Aducanumab Clinical Trial Rollercoaster?
• 

  Alzheimer’s Drugs Worth Repurposing?
• 

  Exergaming and Dementia: Can Exercise Video Games Slow Cognitive Decline?
• 

  Amylyx “Bulletproof Vest for Neurons” Tested as Potential Alzheimer’s Therapy
• 

  Could Arthritis Drug Olumiant Treat Alzheimer’s? A.I. Thinks So
• 

  What’s Next for Eli Lilly Alzheimer’s Drug Donanemab? Trial Enrollment Continues
• 

  Why AC Immune’s Alzheimer’s Vaccine Failed Phase 2 Trials, and What’s Next
• 

  To End Alzheimer’s, Trials Need Volunteers
• 

  Immunotherapy: Boosting Our Immune System to Treat Alzheimer’s Disease
• 

  Exploring a Possible Alzheimer’s Cure With Immunotherapy
• 

  Op-Ed: Why Is It Taking So Long To Stop Neurodegenerative Diseases?
• 

  Quadruple Misfolded Proteins May Explain Why Alzheimer’s Clinical Trials Have Failed
• 

  Can Memory Loss Be Reversed? Experimental Drug Heads to Clinical Trials
• 

  A Safer Dementia-Related Psychosis Treatment Grows Closer to FDA Approval
• 

  Alzheimer’s Drug Trials Have Had a 99% Failure Rate. The Good News: There Are Currently More Than 100 in the Pipeline

Previous789Next